Association between Accessory Gene Regulator Polymorphism and Mortality among Critically Ill Patients Receiving Vancomycin for Nosocomial MRSA Bacteremia: A Cohort Study
Table 2
Univariate Cox regression analysis of risk factors for in-hospital mortality in critically ill patients with MRSA bacteremia treated with vancomycin.
Variable
Mortality group
Survival group
HR (95% CI)
P value
Age years, median (SD)
57.1 (13.6)
52.4 (23.8)
1.01 (0.97–1.05)
0.47
APACHE II score, median (SD)
25.0 (9.1)
23.1 (7.8)
1.01 (0.93–1.11)
0.69
Initial plasma CRP, mg/L, median (SD)
226.0 (100.5)
90.6 (69.2)
1.004 (0.99–1.009)
0.07
Initial serum creatinine, g/dL, mean (SD)
1.9 (1.2)
1.2 (1.4)
1.42 (0.99–2.04)
0.05
MIC for vancomycin > 1 mcg/mL, No (%)
1 (7.1)
4 (57.1)
0.23 (0.03–1.85)
0.17
Appropriate vancomycin serum trough levels, number (%)
8 (57.1)
2 (14.2)
3.05 (0.37–25.11)
0.29
Time to vancomycin administration, days, mean (SD)
